This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
ELISA/assay
product name :
Human uPAR Quantikine ELISA Kit
catalog :
DUP00
quantity :
1 Kit
price :
655 USD
citations: 44
Reference
Murphy J, Zierotin A, Mongan D, Healy C, Susai S, O Donoghue B, et al. Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders - A systematic review and meta-analysis. Brain Behav Immun. 2024;120:327-338 pubmed publisher
Brody G, Yu T, Miller G, Chen E. Longitudinal links between early adolescent temperament and inflammation among young black adults. Psychoneuroendocrinology. 2023;152:106077 pubmed publisher
Joyce J, Cabañas N, Pisharody R, Ouyang B, Patel R, Reiser J, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism. Parkinsonism Relat Disord. 2022;101:39-42 pubmed publisher
Hladunewich M, Cattran D, Sethi S, Hayek S, Li J, Wei C, et al. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin. Kidney Int Rep. 2022;7:68-77 pubmed publisher
Miller G, Chen E, Finegood E, Shimbo D, Cole S. Prospective associations between neighborhood violence and monocyte pro-inflammatory transcriptional activity in children. Brain Behav Immun. 2022;100:1-7 pubmed publisher
Buhelt S, Søndergaard H, Mahler M, Cobanovic S, Börnsen L, Ammitzbøll C, et al. Biomarkers of systemic inflammation, soluble IL-2Rα and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients. Mult Scler Relat Disord. 2021;54:103140 pubmed publisher
Olsson A, Gustavsen S, Langkilde A, Hansen T, Sellebjerg F, Bach Søndergaard H, et al. Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy. Mult Scler Relat Disord. 2021;54:103136 pubmed publisher
Li X, Qi D, Wang M, Ji K, Xie Q, Wang Y, et al. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling Inhibition. J Ethnopharmacol. 2021;279:114351 pubmed publisher
Jehn U, Schütte Nütgen K, Henke U, Pavenstadt H, Suwelack B, Reuter S. Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients. Sci Rep. 2021;11:3713 pubmed publisher
Olsson A, Gustavsen S, Hasselbalch I, Langkilde A, Sellebjerg F, Oturai A, et al. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102520 pubmed publisher
Wajda J, Dumnicka P, Kolber W, Sporek M, Maziarz B, Ceranowicz P, et al. The Marker of Tubular Injury, Kidney Injury Molecule-1 (KIM-1), in Acute Kidney Injury Complicating Acute Pancreatitis: A Preliminary Study. J Clin Med. 2020;9: pubmed publisher
Huang F, Li Y, Xu R, Cheng A, Lv Y, Liu Q. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis. Mediators Inflamm. 2020;2020:7850179 pubmed publisher
An J, Hyeon J, Jung Y, Choi Y, Kim J, Yang S, et al. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis. Sci Rep. 2019;9:14707 pubmed publisher
Winnicki W, Sunder Plassmann G, Sengolge G, Handisurya A, Herkner H, Kornauth C, et al. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Sci Rep. 2019;9:13783 pubmed publisher
Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10:1835 pubmed publisher
Beckert L, Brockway B, Simpson G, Southcott A, Lee Y, Rahman N, et al. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight. 2019;5: pubmed publisher
Shuster S, Ankawi G, Licht C, Reiser J, Wang X, Wei C, et al. Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR. J Clin Med. 2018;7: pubmed publisher
Kolber W, Kusnierz Cabala B, Dumnicka P, Maraj M, Mazur Laskowska M, Pędziwiatr M, et al. Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis. J Clin Med. 2018;7: pubmed publisher
Torino C, Pizzini P, Cutrupi S, Postorino M, Tripepi G, Mallamaci F, et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients. Kidney Int Rep. 2018;3:1100-1109 pubmed publisher
Zhou J, Kwak K, Wu Z, Yang D, Li J, Chang M, et al. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Cell Physiol Biochem. 2018;47:1909-1924 pubmed publisher
Wu W, Cui Y, Hu J, Liao R, Li S, Mo L, et al. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis. Kidney Blood Press Res. 2018;43:664-672 pubmed publisher
Hayek S, Divers J, Raad M, Xu J, Bowden D, Tracy M, et al. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein. J Am Heart Assoc. 2018;7: pubmed publisher
Luo Q, Ning P, Zheng Y, Shang Y, Zhou B, Gao Z. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study. Crit Care. 2018;22:15 pubmed publisher
Koh A, Velmurugan B, Gao F, Tan R, Wong J, Teo L, et al. Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation. BMC Geriatr. 2017;17:275 pubmed publisher
Guthoff M, Wagner R, Randrianarisoa E, Hatziagelaki E, Peter A, Haring H, et al. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep. 2017;7:40627 pubmed publisher
Guo S, Han M, Chen M, Ning Y, Pei G, Li Y, et al. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China. PLoS ONE. 2015;10:e0138718 pubmed publisher
Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, et al. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy. PLoS ONE. 2015;10:e0132869 pubmed publisher
Lane D, Matte I, Garde Granger P, Laplante C, Carignan A, Rancourt C, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492 pubmed publisher
Gilder A, Jones K, Hu J, Wang L, Chen C, Carter B, et al. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. J Biol Chem. 2015;290:14798-809 pubmed publisher
Chang M, Chang H, Chan C, Yeung S, Hsien H, Lin B, et al. p-Cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation/atherosclerosis-related modulators production in endothelial cells and mononuclear cells. PLoS ONE. 2014;9:e114446 pubmed publisher
Spinale J, Mariani L, Kapoor S, Zhang J, Weyant R, Song P, et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int. 2015;87:564-74 pubmed publisher
Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015;87:210-6 pubmed publisher
Huang J, Liu G, Zhang Y, Cui Z, Wang F, Liu X, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12:81 pubmed publisher
Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85:649-58 pubmed publisher
Maas R, Wetzels J, Deegens J. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int. 2012;81:1043-1044 pubmed publisher
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952-60 pubmed publisher
Zuckerman S, Brown J, KAO W. Identification of regulatory Hck and PAI-2 proteins in the monocyte response to PEG-containing matrices. Biomaterials. 2009;30:3825-33 pubmed publisher
Beaufort N, Leduc D, Eguchi H, Mengele K, Hellmann D, Masegi T, et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1263-72 pubmed
Brooks A, Bates M, Vrtis R, Jarjour N, Bertics P, Sedgwick J. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am J Respir Cell Mol Biol. 2006;35:503-11 pubmed
Lash G, Otun H, Innes B, Bulmer J, Searle R, Robson S. Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system. Biol Reprod. 2006;74:403-9 pubmed
Wang J, Stockton D, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004;10:6169-78 pubmed
Cobos E, Jumper C, Lox C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin Appl Thromb Hemost. 2003;9:241-6 pubmed
Rigolin G, Tieghi A, Ciccone M, Bragotti L, Cavazzini F, Della Porta M, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol. 2003;120:953-9 pubmed
Jumper C, Cobos E, Lox C. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSC. Anticancer Res. 2002;22:2073-6 pubmed
product information
master code :
DUP00
SKU :
DUP00
product name :
Human uPAR Quantikine ELISA Kit
unit size :
1 Kit
description :
The Human uPAR Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human uPAR in cell culture supernates (10 ul), serum (10 ul), edta plasma (10 ul), heparin plasma (10 ul), urine (10 ul).
target :
uPAR
category :
ELISAs
species :
Human
specificity :
Natural and recombinant human uPAR
gene symbol :
PLAUR
kit type :
Solid Phase Sandwich ELISA
assay length :
4.5 hours
elisaSampleTypes :
Cell Culture Supernates (10 uL), Serum (10 uL), EDTA Plasma (10 uL), Heparin Plasma (10 uL), Urine (10 uL)
elisaSensitivity :
33 pg/mL
elisaRange :
62.50 - 4000 pg/mL
top caption :
Human uPAR ELISA Standard Curve
applications :
ELISA
USD :
655 USD
product details :
The Quantikine Human uPAR Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human uPAR in cell culture supernates, serum, plasma, and urine. It contains NS0-expressed recombinant human uPAR and antibodies raised against the recombinant factor. It has been shown to accurately quantitate the recombinant factor. Results obtained using natural human uPAR showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values of natural human uPAR.
alt names :
CD87, CD87 antigen, Monocyte activation antigen Mo3, plasminogen activator, urokinase receptor, PLAUR, uPAR, U-PAR, UPARurokinase plasminogen activator surface receptor, u-plasminogen activator receptor form 2, URKRMO3
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.